This inventor holds 1 USPTO granted patent. Top assignee: Remegen, Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Fang Yang: Innovator in Antibody-Drug Conjugates
Introduction
Fang Yang is a notable inventor based in Yantai, China. He has made significant contributions to the field of biotechnology, particularly in the development of innovative therapeutic solutions. His work focuses on antibody-drug conjugates, which are crucial in targeted cancer therapies.
Latest Patents
Fang Yang holds a patent for an "ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF." This invention represents a promising advancement in the treatment of cancers that express Claudin 18.2, showcasing his commitment to improving patient outcomes through innovative medical solutions. He has 1 patent to his name.
Career Highlights
Fang Yang is currently employed at Remegen Ltd., a company dedicated to developing innovative biopharmaceuticals. His role at Remegen has allowed him to work on cutting-edge research and contribute to the advancement of cancer therapies.
Collaborations
Fang has collaborated with notable colleagues, including Jianmin Fang and Yuanhao Li. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic approaches.
Conclusion
Fang Yang's contributions to the field of biotechnology, particularly through his patent on antibody-drug conjugates, highlight his role as an innovator in cancer treatment. His work at Remegen Ltd. and collaborations with esteemed colleagues further emphasize his impact on the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile